10.6084/M9.FIGSHARE.21382877
Daniele Giardiello
Daniele
Giardiello
Leiden University Medical Center
European Academy of Bozen
Antoni van Leeuwenhoek Hospital
Institute for Biomedicine
Maartje J. Hooning
Maartje J.
Hooning
Erasmus MC Cancer Institute
Michael Hauptmann
Michael
Hauptmann
Medizinische Hochschule Brandenburg Theodor Fontane
Renske Keeman
Renske
Keeman
Antoni van Leeuwenhoek Hospital
B. A. M. Heemskerk-Gerritsen
B. A. M.
Heemskerk-Gerritsen
Erasmus MC Cancer Institute
Heiko Becher
Heiko
Becher
University Medical Center Hamburg-Eppendorf
Carl Blomqvist
Carl
Blomqvist
Örebro University Hospital
University of Helsinki
Stig E. Bojesen
Stig E.
Bojesen
Copenhagen University Hospital
Herlev and Gentofte Hospital
University of Copenhagen
Manjeet K. Bolla
Manjeet K.
Bolla
University of Cambridge
Nicola J. Camp
Nicola J.
Camp
University of Utah
Kamila Czene
Kamila
Czene
Karolinska Institute
Peter Devilee
Peter
Devilee
Leiden University Medical Center
Diana M. Eccles
Diana M.
Eccles
University of Southampton
Peter A. Fasching
Peter A.
Fasching
University of California, Los Angeles
Universitätsklinikum Erlangen
Jonine D. Figueroa
Jonine D.
Figueroa
University of Edinburgh
National Cancer Institute
Henrik Flyger
Henrik
Flyger
Copenhagen University Hospital
Montserrat García-Closas
Montserrat
García-Closas
National Cancer Institute
Christopher A. Haiman
Christopher A.
Haiman
University of Southern California
Ute Hamann
Ute
Hamann
German Cancer Research Center
John L. Hopper
John L.
Hopper
University of Melbourne
Anna Jakubowska
Anna
Jakubowska
Pomeranian Medical University
Floor E. Leeuwen
Floor E.
Leeuwen
Antoni van Leeuwenhoek Hospital
Annika Lindblom
Annika
Lindblom
Karolinska University Hospital
Karolinska Institute
Jan Lubiński
Jan
Lubiński
Pomeranian Medical University
Sara Margolin
Sara
Margolin
Stockholm South General Hospital
Karolinska Institute
Maria Elena Martinez
Maria Elena
Martinez
University of California, San Diego
Heli Nevanlinna
Heli
Nevanlinna
University of Helsinki
Ines Nevelsteen
Ines
Nevelsteen
Universitair Ziekenhuis Leuven
Saskia Pelders
Saskia
Pelders
Erasmus MC Cancer Institute
Paul D. P. Pharoah
Paul D. P.
Pharoah
University of Cambridge
Sabine Siesling
Sabine
Siesling
Netherlands Comprehensive Cancer Organisation
University of Twente
Melissa C. Southey
Melissa C.
Southey
Monash University
University of Melbourne
Cancer Council Victoria
Annemieke H. van der Hout
Annemieke H.
van der Hout
University Medical Center Groningen
Liselotte P. van Hest
Liselotte P.
van Hest
Vrije Universiteit Amsterdam
Jenny Chang-Claude
Jenny
Chang-Claude
University Medical Center Hamburg-Eppendorf
University Cancer Center Hamburg
German Cancer Research Center
Per Hall
Per
Hall
Stockholm South General Hospital
Karolinska Institute
Douglas F. Easton
Douglas F.
Easton
University of Cambridge
Ewout W. Steyerberg
Ewout W.
Steyerberg
Leiden University Medical Center
Erasmus MC Cancer Institute
Erasmus MC
Erasmus University Rotterdam
Marjanka K. Schmidt
Marjanka K.
Schmidt
Antoni van Leeuwenhoek Hospital
Additional file 1 of PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients
Additional file 1. Supplementary methods also including the following tables and figures Table S2. List of BCAC studies (including ABCS source) with the corresponding country and geographic area. Table S4: Clinical utility of the 5-year contralateral breast cancer risk prediction models (PredictCBC-1A with PredictCBC-2.0A and PredictCBC-1B with PredictCBC-2.0B). Figure S1. Visual assessment of calibration through calibration plots in the internal–external cross-validation at 5 years for the PredictCBC-2.0A model. Figure S2. Visual assessment of calibration through calibration plots in the internal–external cross-validation at 10 years for the PredictCBC-2.0A model. Figure S3. Visual assessment of calibration through calibration plots in the internal–external cross-validation at 5 years for the PredictCBC-2.0B model. Figure S4. Visual assessment of calibration through calibration plots in the internal–external cross-validation at 10 years for the PredictCBC-2.0B model. Figure S5. Density distribution of 5-year predicted contralateral breast cancer using PredictCBC-2.0 models. Figure S6. Decision curve analysis at 5 years for the contralateral breast cancer risk models (PredictCBC and PredictCBC-2.0) including BRCA mutation information.
Genetics
Biotechnology
69999 Biological Sciences not elsewhere classified
Cancer
Science Policy
figshare
2022
2022-10-22
2022-10-22
Journal contribution
1662682 Bytes
10.1186/s13058-022-01567-3
CC BY + CC0